Stay updated with breaking news from Interim Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches.
Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant...
Treatment with setrusumab (UX143) for at least 6 months resulted in 67% reduction in annualized fracture rate in patients with OI in Phase 2/3 Orbit study
Treatment with setrusumab for at least 6 months resulted in 67% reduction in annualized fracture rate in patients with OI in Phase 2/3 Orbit study Quantitative data from the Phase 1/2 study of...
/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, will be presenting positive...